Dr. Reddy’s Fosaprepitant API offerings
Fosaprepitant is indicated for preventing acute and delayed nausea and vomiting associated with moderately or highly emetogenic chemotherapy combined with other antiemetic agents. The US FDA and EMA approved fosaprepitant in 2008, and the PMDA in 2011. As of December 2020, this corresponds to an API demand of 500 kg per year (IQVIA MAT).
We offer stable amorphous API which meets global regulatory requirements and formulation needs of customers. To know more about Dr. Reddy’s Fosaprepitant offerings Read the technical sheet on this topic by filling the contact form below.
Explore other Whitepapers:Know More
- Email us: firstname.lastname@example.org
- +91 40 49002222
Please fill the Contact form below in order to view the white paper